LOGIN  |  REGISTER
Chimerix
Recursion

Claritev Announces Participation at Upcoming Conferences

August 27, 2025 | Last Trade: US$29.20 0.00 0.00

MCLEAN, Va. / Aug 27, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in person at the following conferences in September 2025:

  • 2025 Wells Fargo Healthcare Conference – Wednesday, September 3, 2025, at the Encore Boston Harbor, Boston, MA (including a presentation at approximately 8:45 am Eastern Time)
  • Morgan Stanley 23rd Annual Global Healthcare Conference – Tuesday, September 9, 2025, at the Sheraton New York Times Square Hotel, New York, NY (including a fireside chat at approximately 4:05 pm Eastern Time)

A live webcast and audio archive of the events will be available through the investor relations section of Claritev’s website at investors.claritev.com/events-and-presentations.

About Claritev

Claritev, formerly known as MultiPlan, is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the healthcare system. Led by a team of deeply experienced associates, data scientists and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose–built solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page